SYNTHESIS OF ESTRONE-OPIOID PEPTIDE ANALOGUE WITH EXPECTED ANALGESIC ACTIVITY

2010 ◽  
Vol 13 (2) ◽  
pp. 20-31
Author(s):  
Ayad A. AL-Hamashi ◽  
◽  
Kawkab Y. Saour ◽  
Science ◽  
1994 ◽  
Vol 266 (5193) ◽  
pp. 2019-2022 ◽  
Author(s):  
C. Dooley ◽  
N. Chung ◽  
B. Wilkes ◽  
P. Schiller ◽  
J. Bidlack ◽  
...  

1989 ◽  
Vol 26 (1-12) ◽  
pp. 73-75 ◽  
Author(s):  
H. Saji ◽  
D. Tsutsumi ◽  
J. Konishi ◽  
A. Yokoyama ◽  
Y. Kiso ◽  
...  

Open Medicine ◽  
2007 ◽  
Vol 2 (4) ◽  
pp. 417-429
Author(s):  
Irina Jaba ◽  
Bogdan Tamba ◽  
Georgios Manolidis ◽  
Ostin Mungiu

AbstractShort fragments of typical or atypical opioid peptides, lacking the whole four amino acid sequence of the enkephalin motif, can preserve a significant percentage of the analgesic activity of the original peptides. This paper investigates the importance of the amino-acidic sequence of minimum structure typical opioid peptides for the analgesic activity. Different groups of rats were treated with 1) Gly-Tyr, 0.5 mg/rat i.t., 2) Tyr-Gly, 0.5 mg/rat i.t., 3) Tyr-Gly-Gly, 0.5 mg/rat i.t., 4) Gly-Gly-Phe-Leu, 0.5 mg/rat i.t., 5) Leu-enkephalin, 0.5 mg/rat i.t.. The analgesic effect of the tested substances was appreciated through the nociceptive threshold for thermal (plantar test) and mechanical nociception (algesimetric test). Fragments of typical opioid peptides elicited antinociceptive activity only when a tyrosine residue was present at the N-terminal end of the amino-acidic sequence. The presence of Nterminal tyrosine provides affinity for the opioid receptors and significant analgesic activity. The intensity of the antinociceptive effect was directly proportional with the length of the amino-acidic sequence. The inhibition of the analgesic effect by previous administration of naloxone proves that this effect is mediated through the opioid system.


Life Sciences ◽  
2001 ◽  
Vol 69 (9) ◽  
pp. 1023-1028 ◽  
Author(s):  
Mitsuaki Yamazaki ◽  
Tsutomu Suzuki ◽  
Minoru Narita ◽  
Andrzej W. Lipkowski

1991 ◽  
Vol 33 (3-4) ◽  
pp. 382-387 ◽  
Author(s):  
B. S. Silbert ◽  
A. W. Lipkowski ◽  
M. S. Cepeda ◽  
S. K. Szyfelbein ◽  
P. F. Osgood ◽  
...  

Peptides ◽  
2008 ◽  
Vol 29 (4) ◽  
pp. 633-638 ◽  
Author(s):  
Jakub Fichna ◽  
Jean-Claude do-Rego ◽  
Nga N. Chung ◽  
Jean Costentin ◽  
Peter W. Schiller ◽  
...  

Author(s):  
George D. Pappas ◽  
Jacqueline Sagen

We have been interested in the use of neural transplants mainly as a local source of neuroactive substances, rather than as a replacement for damaged neural circuities. In particular, we have been exploring the possibilities of reducing pain by transplants of opioid peptide producing cells, and reducing depression by transplants of monoamine-producing cells. For the past several years, work in our laboratory has demonstrated in both acute and chronic pain models that transplantation of adrenal medullary tissue or isolated chromaffin cells into CNS pain modulatory regions can reduce pain sensitivity in rodents. Chromaffin cells were chosen as donor source since they produce high levels of both opioid peptides and catecholamines, substances which independently, and probably synergistically, reduce pain sensitivity when injected locally into the spinal cord. The analgesia produced by these transplants most likely results from the release of both opioid peptides and catecholamines, since it can be blocked or attenuated by opiate or adrenergic antagonists, respectively. Furthermore, CSF levels of met-enkephalin and catecholamines are increased by the transplants.


Sign in / Sign up

Export Citation Format

Share Document